A new therapeutic and diagnostic device for normobaric intermittent hypoxia hyperoxia therapy (IHHT) with biofeedback - ReOxy®.
About the device
The ReOxy° device is manufactured in Germany, registered in the Ministry of health of the Russian Federation (registration certificate of the Ministry of health of the Russian Federation №.РЗН 2014/1486 dated 30.04.2019) and has no complete analog in Russia. ReOxy is a unique hypoxytherapy device, made in accordance with the requirements of the European medical Directive MDD 93/42/EEC and has a CE certificate of conformity, which guarantees the effectiveness and safety of its use in medicine.
The main feature of the device ReOxy® is SRT® technology, which allows device to automatically calculate the most effective and at the same time safe "dosage" of the training factor (intensity and duration of exposure to hypoxia and hyperoxia) based on the individual functional indicators of the patient. More simply, the device itself selects the parameters of the procedure individually for each patient so that it is harmless and effective.
Innovative solutions, implemented in the ReOxy® device:
Mode "Hypoxia-Hyperoxia" - cycles of hypoxia (10-15 % О2) are replaced by cycles of hyperoxia (30-40% O2), which significantly increases the amplitude of the affecting training factor without increasing the risk of undesirable consequences;
Unique patented SRT® technology - automatic calculation of the maximum effective "dose" of the training factor (intensity and duration of exposure to hypoxia and hyperoxia) based on individual functional indicators of the patient;
Physiological feedback - correction of the procedure parameters in response to changes in individual functional indicators (SpO2, heart rate, rate of decrease in saturation and recovery);
Operative medical control - monitoring of vital indicators of the patient's body throughout the procedure;
Integrated safety system – a multi-level impact safety system , which does not allow vital physiological parameters to go beyond acceptable limits;
Mobility, compactness- the ReOxy® device is made in a single case, does not require the connection to additional devices, does not require a separate room and it is easy to transfer.
Rehabilitation after COVID-19
A unique rehabilitation program after COVID-19 at the European Medical Center (EMC): professional international team of more than 600 medical experts from the USA, Western Europe, Israel and Russia.
Rehabilitation after COVID-19
The method of intermittent hypoxia hyperoxia therapy (IHHT) is a non-drug method that is used for treatment and rehabilitation by increasing the functional reserves of the body through improved delivery and utilization of oxygen. The method is based on the individually dosed use of hypoxic (with a decrease in oxygen content) gas mixtures at normal atmospheric pressure in an interval mode – breathing with a hypoxic gas mixture alternates with periods of reoxygenation (recovery).
Indications for the use of IHHT during the pandemic:
Rehabilitation after pneumonia and the consequences of a long stay on artificial ventilation
Reducing the consequences of a sharp reduction in physical activity due to long-term self-isolation
Prevention of complications of COVID-19
Prevention of heart attack and stroke, especially in people with risk factors (hypertension, overweight, diabetes, coronary heart disease, chronic respiratory diseases) in conditions of prolonged self-isolation and forced restriction of physical activity
Currently, this method is used in clinical practice for the treatment and rehabilitation of patients with chronic bronchopulmonary, cardiovascular and metabolic diseases. The method has a minimum of contraindications, has no age restrictions, is easy to implement and is well tolerated by patients. The absolute advantage of the IHHT method is its compatibility with traditional methods of treatment and the ability to potentiate the action of pharmacological drugs.
In patients with bronchopulmonary diseases, the following physiological effects were noted in the presented scientific publications:
In adults, after a course of IHHT, the alveolar ventilation index increases by 20%, the AV/MOD ratio significantly increases, which indicates an increasing efficiency of external respiration. The oxygen consumption increases by 6%, the ventilation equivalent decreases by 15%, and the oxygen effect of the respiratory cycle significantly increases.
Taking into account that patients after COVID-19 are weakened and have functional disorders, due to the presence of accompanying pathology, the main requirements for IHHT are:
In order to ensure sanitary and hygienic requirements, the latest generation devices have a multi-stage filtration and cleaning system for the supplied gas mixture, as well as an external port (connector) for connecting the individual respiratory circuit through an antibacterial/ antiviral filter, which provides protection from viral and bacterial contamination of both the patient and the device. The use of a two-port mask as part of an individual respiratory circuit provides a unidirectional flow of the gas mixture from the device to the patient, and exhalation is carried out into the environment.
Open the full list of partners (30+ organizations)